Larimar Therapeutics Income Statement (2013-2020) | LRMR

1Y3Y5Y7Y10YAll
Download Data
Income Statement Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020
Revenue & cost
Revenue -0.00M-0.44M-0.21M-0.21M-0.21M-0.21M-0.20M-0.18M-0.16M-0.14M-0.13M-0.10M-0.07M-0.05M-0.03M-0.01M-0.46M-0.47M-0.47M-0.50M-0.50M-0.48M-0.43M-0.36M-0.30M
Operating items
Research & Development 3.27M4.70M12.08M7.34M10.21M12.53M14.17M17.71M12.50M10.16M10.00M7.28M9.68M10.53M9.72M10.91M12.43M12.21M11.83M11.46M9.63M8.57M5.26M0.42M
Selling, General & Administrative 1.25M1.29M2.29M3.32M3.02M5.08M5.55M5.54M5.36M4.90M4.83M3.20M3.59M3.01M3.12M2.45M3.27M3.35M3.34M3.23M3.65M3.62M3.63M5.32M3.65M
Restructuring Costs 4.02M1.53M0.01M
Other Operating Expenses 3.52M3.76M-0.09M
Operating Expenses 3.52M3.76M4.52M5.99M14.36M10.66M13.24M17.61M19.72M23.25M17.86M15.06M14.83M10.47M13.27M13.54M12.84M13.36M15.70M15.56M15.17M14.69M13.28M12.19M12.91M7.28M3.56M
Operating Income -4.52M-5.99M-14.36M-10.66M-13.24M-17.61M-19.72M-23.25M-17.86M-15.06M-14.83M-10.47M-13.27M-13.54M-12.84M-13.36M-15.70M-15.56M-15.17M-14.69M-13.28M-12.19M-12.91M-7.28M-3.56M
EBIT -4.52M-5.99M-14.36M-10.66M-13.24M-17.61M-19.72M-23.25M-17.86M-15.06M-14.83M-10.47M-13.27M-13.54M-12.84M-13.36M-15.70M-15.56M-15.17M-14.69M-13.28M-12.19M-12.91M-7.28M-3.56M
Non-operating items
Non Operating Investment Income -0.00M
Interest & Investment Income 0.00M0.03M0.04M0.06M0.14M0.19M0.21M0.23M0.23M0.23M0.23M0.25M0.27M0.26M0.27M0.32M0.62M0.68M0.64M0.56M0.45M0.34M0.26M
Other Non Operating Income 0.07M0.03M-0.12M-0.08M-0.06M0.00M-0.11M0.06M0.07M-0.05M0.06M-0.10M0.10M-0.01M0.02M0.03M-0.06M-0.07M-0.05M-0.06M0.02M-0.02M-0.03M0.06M0.22M
Non Operating Income 0.06M-0.41M-0.33M-0.27M-0.23M-0.15M-0.17M0.07M0.12M0.03M0.16M0.04M0.25M0.19M0.26M0.27M-0.25M-0.21M0.10M0.12M0.17M0.06M-0.01M0.03M0.22M
Net income details
EBT -4.52M-6.43M-14.57M-10.85M-13.41M-17.76M-19.77M-23.23M-17.81M-14.98M-14.73M-10.34M-13.11M-13.34M-12.61M-13.11M-15.89M-15.70M-15.02M-14.52M-13.13M-12.11M-12.88M-7.31M-3.61M
Profit After Tax -4.46M-6.40M-14.69M-10.93M-13.47M-17.76M-19.88M-23.17M-17.74M-15.03M-14.68M-10.44M-13.01M-13.35M-12.59M-13.09M-15.96M-15.78M-15.07M-14.57M-13.11M-12.13M-12.91M-7.25M-3.60M
Income from Continuing Operations -4.52M-6.43M-14.57M-10.85M-13.41M-17.76M-19.77M-23.23M-17.81M-14.98M-14.73M-10.34M-13.11M-13.34M-12.61M-13.11M-15.89M-15.70M-15.02M-14.52M-13.13M-12.11M-12.88M-7.31M-3.61M
Consolidated Net Income -4.52M-6.43M-14.57M-10.85M-13.41M-17.76M-19.77M-23.23M-17.81M-14.98M-14.73M-10.34M-13.11M-13.34M-12.61M-13.11M-15.89M-15.70M-15.02M-14.52M-13.13M-12.11M-12.88M-7.31M-3.61M
Income towards Parent Company -4.52M-6.43M-14.57M-10.85M-13.41M-17.76M-19.77M-23.23M-17.81M-14.98M-14.73M-10.34M-13.11M-13.34M-12.61M-13.11M-15.89M-15.70M-15.02M-14.52M-13.13M-12.11M-12.88M-7.31M-3.61M
Preferred Dividend Payments 0.05M0.04M
Net Income towards Common Stockholders -3.56M-3.90M-4.51M-6.44M-14.69M-10.93M-13.47M-17.76M-19.88M-23.17M-17.74M-15.03M-14.68M-10.44M-13.01M-13.35M-12.59M-13.09M-15.96M-15.78M-15.07M-14.57M-13.13M-12.11M-12.88M-7.31M-3.61M
Additional items
EPS (Basic) -4.88-5.35-6.18-2.96-0.65-0.48-0.53-0.66-0.73-0.85-0.65-0.55-0.54-0.38-0.48-0.49-0.46-0.48-0.58-0.57-0.41-0.39-0.35-0.32-0.35-0.19-0.10
Shares Outstanding (Weighted Average) 1.73M1.73M1.89M1.89M2.24M2.24M2.26M2.27M2.27M2.27M2.28M2.28M2.28M2.28M2.29M2.29M2.30M2.30M3.07M3.07M3.11M3.11M3.11M3.11M3.12M3.12M15.36M
Shares Outstanding (Diluted Average) 9.38M15.98M
EBITDA -4.46M-6.40M-14.69M-10.97M-13.48M-17.78M-19.86M-23.35M-17.53M-15.04M-14.73M-10.45M-12.99M-13.32M-12.57M-13.12M-15.95M-15.73M-15.09M-14.57M-13.08M-12.10M-12.90M-7.26M-3.60M
Interest Expenses 0.00M0.44M0.21M0.21M0.21M0.21M0.20M0.18M0.16M0.14M0.13M0.10M0.07M0.05M0.03M0.01M0.46M0.47M0.47M0.50M0.50M0.48M0.43M0.36M0.30M